Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast

OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug developers given the persistent unmet need for more effective and safe therapies, particularly those with a novel and distinct mechanism of action that strongly correlates with the nature of this type of pain. OA pain is predominantly treated with cost-effective generic NSAIDs and opioid analgesics, although branded agents such as costly abuse-deterrent reformulations of opioid analgesics, new combinations of existing NSAIDs that attempt to mitigate side effects, and intra-articular injections are also frequently prescribed in later lines of therapy. Emerging therapies, such as biological drugs from Pfizer / Eli Lilly and Regeneron / Teva / Mitsubishi Tanabe Pharma targeting NGF, and the increasing number of patients diagnosed with OA pain due to lifestyle influences will be key drivers for growth through 2028.

Questions answered:

  • How do interviewed experts perceive the OA pain marketplace to be changing given the emphasis on the risk of abuse / misuse with opioid analgesics?
  • What effect will the recent launches of new analgesics such as Flexion Therapeutics' Zilretta and Iroko’s Vivlodex continue to have on the treatment paradigm?
  • What will the impact of a new drug class, the anti-NGF biologics, be on the treatment landscape given their demonstrably robust efficacy tempered by lingering concerns about safety issues seen in clinical trials?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Thirteen country-specific interviews with thought-leading pain specialists and rheumatologists, supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed prevalence and drug-treated rates of OA pain by country.

Emerging therapies: Phase III / preregistration / registration: 8 drugs; Phase II: 7 drugs; coverage of select Phase I products.

Market forecast features: 10-year, annualized, drug-level sales and patient share of key analgesics through 2028, segmented by brands / generics.

Key companies: Acorda Therapeutics, Ampio Pharmaceuticals, Astellas, Centrexion, Collegium Pharmaceutical, Eli Lilly, Flexion Therapeutics, Iroko Pharmaceuticals, Mitsubishi Tanabe Pharma, Nektar Therapeutics, Pfizer, Purdue Pharma, Regeneron, Samumed, Teva.

Key drugs: acetaminophen / hydrocodone, Ampion, cebranopadol, celecoxib, CNTX-4975, fasinumab, Hysingla ER (hydrocodone ER), lorecivivint, Nucynta IR / ER (tapentadol IR / ER), oxycodegol (NKTR-181), oxycodone CR (OxyContin, generics), oxycodone ER (Xtampza ER), Qutenza (8% capsaicin patch), tanezumab, tramadol, Vivlodex (meloxicam, low dose), Zilretta (triamcinolone ER, injectable).

Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Osteoarthritic Pain - Landscape & Forecast - Disease Landscape & Forecast
    • Key Findings
      • Osteoarthritic Pain u2013 Key Findings u2013 May 2020
    • Key Updates
      • May 2020
        • November 2019
          • September 2019
            • June 2019
              • January 2019
              • Market Outlook
                • Key Findings
                  • A Note on Emerging Therapies
                  • Market Share of Osteoarthritic Pain Drug Classes: 2018
                  • Market Share of Osteoarthritic Pain Drug Classes: 2028
                  • Osteoarthritic Pain SWOT Analysis
                • COVID-19: Areas of Potential Forecast Impact
                  • Market Drivers and Constraints
                    • What Factors Are Driving the Market for Osteoarthritic Pain?
                    • What Factors Are Constraining the Market for Osteoarthritic Pain?
                    • Major-Market Sales of Select Drug Classes in Osteoarthritic Pain: 2018-2028
                    • Major-Market Patient Share of Select Drug Classes in Osteoarthritic Pain: 2018-2028
                  • Drug-Class-Specific Trends
                    • Major-Market Sales of COX-2-Selective NSAIDs: 2018-2028
                    • Major-Market Patient Share of COX-2-Selective NSAIDs: 2018-2028
                    • Major-Market Sales of Select Cytokine Inhibitors: 2018-2028
                    • Major-Market Patient Share of Select Cytokine Inhibitors: 2018-2028
                    • Major-Market Sales of Dual-Acting Opioid Analgesics: 2018-2028
                    • Major-Market Patient Share of Dual-Acting Opioid Analgesics: 2018-2028
                    • Major-Market Sales of Local Anesthetics: 2018-2028
                    • Major-Market Patient Share of Local Anesthetics: 2018-2028
                    • Major-Market Sales of Key Prescription NSAIDs: 2018-2028
                    • Major-Market Patient Share of Key Prescription NSAIDs: 2018-2028
                    • Major-Market Sales of Key Opioid Analgesics: 2018-2028
                    • Major-Market Patient Share of Key Opioid Analgesics: 2018-2028
                    • Major-Market Sales of Opioid / Acetaminophen Combinations: 2018-2028
                    • Major-Market Patient Share of Opioid / Acetaminophen Combinations: 2018-2028
                    • Major-Market Sales of Select Viscosupplements: 2018-2028
                    • Major-Market Patient Share of Viscosupplements: 2018-2028
                    • Major-Market Sales of Anti-NGF Therapies: 2018-2028
                    • Major-Market Patient Share of Anti-NGF Therapies: 2018-2028
                    • Major-Market Sales and Patient Share of Wnt Pathway Inhibitors: 2018-2028
                • Forecast
                  • Market Forecast Downloads
                  • Market Forecast Assumptions - Osteoarthritic Pain (2018-2028) - May 2020
                  • Market Forecast Dashboard - Osteoarthritic Pain (2018-2028) - May 2020
                • Etiology and Pathophysiology
                  • Disease Overview
                    • Pathophysiology of OA
                      • Risk Factors Associated with the Development of Osteoarthritis
                      • Anatomy of the Healthy Synovial Joint: The Knee
                    • Normal Mechanisms of Pain Transmission
                      • Ascending and Descending Pathways in Osteoarthritic Pain
                      • Dorsal Root Ganglion Synapse
                    • Etiology of Osteoarthritis Pain
                      • Etiology of Osteoarthritic Pain: Inflammatory Pain
                      • Etiology of Osteoarthritic Pain: Peripheral and Central Sensitization
                      • Effect of NSAIDs on the Inflammatory Pathway
                    • Key Pathways and Drug Targets
                      • Select Drug Targets and Therapies in Development for Osteoarthritic Pain
                  • Epidemiology
                    • Key Findings
                      • Epidemiology Populations
                        • Disease Definition
                        • Methods
                        • Sources Used for Diagnosed Prevalent Cases of Osteoarthritic Pain
                        • Number of Diagnosed Prevalent Cases of Osteoarthritic Pain in the Major Pharmaceutical Markets: 2018-2028 (thousands)
                        • Drug-Treated Prevalent Cases of Osteoarthritic Pain: 2018-2028 (thousands)
                    • Current Treatment
                      • Key Findings
                        • Treatment Goals
                          • Key Endpoints Used in Clinical Trials for Osteoarthritic Pain
                        • Key Current Therapies
                          • Overview
                          • Mechanism of Action of Key Current Drug Classes Used for Osteoarthritic Pain
                          • Current Treatments Used for Osteoarthritic Pain
                          • Market Events Impacting the Use of Key Current Therapies for Osteoarthritic Pain
                          • Expert Insight: NSAIDs
                          • Advantages and Disadvantages of Ibuprofen
                          • Advantages and Disadvantages of Naproxen
                          • Advantages and Disadvantages of Oral / Topical Diclofenac
                          • Advantages and Disadvantages of Low-Dose Meloxicam
                          • Expert Insight: COX-2-Selective NSAIDs
                          • Advantages and Disadvantages of Celecoxib
                          • Advantages and Disadvantages of Etoricoxib
                          • Expert Insight: Opioid Analgesics
                          • Advantages and Disadvantages of Oxycodone
                          • Advantages and Disadvantages of Hydrocodone / Acetaminophen
                          • Expert Insight: Dual-Acting Opioid Analgesics
                          • Advantages and Disadvantages of Tramadol IR / ER
                          • Advantages and Disadvantages of Tapentadol IR / ER
                          • Expert Insight: Cytokine Inhibitors
                          • Advantages and Disadvantages of Triamcinolone ER
                          • Results from Select Clinical Trials Investigating Triamcinolone ER for the Treatment of Osteoarthritic Pain
                          • Key Ongoing Clinical Trials of Triamcinolone ER in the Treatment of Osteoarthritic Pain
                          • Expert Insight: Viscosupplements
                          • Advantages and Disadvantages of Synvisc / Synvisc-One
                          • Advantages and Disadvantages of Orthovisc
                        • Medical Practice
                          • Overview
                          • Regional Osteoarthritic Pain Treatment Guidelines
                          • Factors Influencing Drug Selection in Osteoarthritic Pain
                          • Treatment Decision Tree for Osteoarthritic Pain: United States
                          • Treatment Decision Tree for Osteoarthritic Pain: Europe
                          • Treatment Decision Tree for Osteoarthritic Pain: Japan
                      • Unmet Need Overview
                        • Current and Future Attainment of Unmet Needs in Osteoarthritic Pain
                        • Top Unmet Needs in Osteoarthritic Pain: Current and Future Attainment
                        • Expert Insight: Unmet Need in Osteoarthritic Pain
                      • Emerging Therapies
                        • Key Findings
                          • Pipeline Trends for Osteoarthritic Pain
                        • Key Emerging Therapies
                          • Key Emerging Therapies in Development for Osteoarthritic Pain
                          • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Osteoarthritic Pain
                          • NSAIDs / COX-2-Selective NSAIDs in Development Likely to Be Prescribed for Osteoarthritic Pain
                          • Expert Insight: Emerging NSAID / COX-2-Selective NSAID Reformulations
                          • Expectations for Launch and Sales Opportunity of NSAID / COX-2-Selective NSAID Reformulations in Osteoarthritic Pain
                          • Ampion Profile
                          • Analysis of the Clinical Development Program for Ampion
                          • Expert Insight: Ampion
                          • Expectations for Launch and Sales Opportunity of Ampion in Osteoarthritic Pain
                          • CNTX-4975 Profile
                          • Analysis of the Clinical Development Program for CNTX-4975
                          • Expert Insight: CNTX-4975
                          • Expectations for Launch and Sales Opportunity of CNTX-4975 in Osteoarthritic Pain
                          • Oxycodegol (NKTR-181) Profile
                          • Analysis of Clinical Development Program for Oxycodegol (NKTR-181)
                          • Expert Insight: Oxycodegol (NKTR-181)
                          • Expectations for Launch and Sales Opportunity of Oxycodegol (NKTR-181) in Osteoarthritic Pain
                          • Cebranopadol Profile
                          • Analysis of the Clinical Development Program for Cebranopadol
                          • Expert Insight: Cebranopadol
                          • Expectations for Launch and Sales Opportunity of Cebranopadol in Osteoarthritic Pain
                          • Fasinumab Profile
                          • Key Ongoing Clinical Trials of Fasinumab in the Treatment of Osteoarthritic Pain
                          • Analysis of the Clinical Development Program for Fasinumab
                          • Expectations for Launch and Sales Opportunity of Fasinumab in Osteoarthritic Pain
                          • Key Results from Select Pivotal Clinical Trials Investigating Tanezumab for the Treatment of Osteoarthritic Pain
                          • Key Ongoing Clinical Trials of Tanezumab in the Treatment of Osteoarthritic Pain
                          • Analysis of the Clinical Development Program for Tanezumab
                          • Expectations for Launch and Sales Opportunity of Tanezumab in Osteoarthritic Pain
                          • Expert Insight: Anti-NGF Therapies
                          • Lorecivivint Profile
                          • Analysis of the Clinical Development Program for Lorecivivint
                          • Expert Insight: Lorecivivint
                          • Expectations for Launch and Sales Opportunity of Lorecivivint in Osteoarthritic Pain
                        • Early-Phase Pipeline Analysis
                          • Select Therapies in Early-Phase Development Likely to Be Prescribed for Osteoarthritic Pain
                          • Role of Disease-Modifying Therapies in Development for Osteoarthritis
                          • Disease-Modifying Therapies Being Investigated for Osteoarthritis
                      • Access & Reimbursement Overview
                        • Region-Specific Reimbursement Practices
                          • Key Market Access Considerations in Osteoarthritic Pain: United States
                          • General Reimbursement Environment: United States
                          • Key Market Access Considerations in Osteoarthritic Pain: EU5
                          • General Reimbursement Environment: EU5
                          • Key Market Access Considerations in Osteoarthritic Pain: Japan
                          • General Reimbursement Environment: Japan
                        • Looking for More?
                      • Appendix
                        • Key Abbreviations Related to Osteoarthritic Pain
                        • Brands, Marketers, and Generic Availability of Key Therapies for Osteoarthritic Pain by Market
                        • Osteoarthritic Pain Bibliography